Grifols, S.A. (GRFS)
NEUTRALFundamental
73
मूल्य
$8.05
मार्केट कैप
$5.45B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$2.01B
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
शुद्ध आय
$172M
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
Free Cash Flow
$573M
कुल इक्विटी
$1.23B
कुल देनदारियाँ
$9.36B
Current Ratio
2.37
Interest Coverage
-
Debt/EBITDA
5.69
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$12.87
वर्तमान मूल्य
$8.05
Margin of Safety
+37.5%
Fair Value सीमा
$8.36 - $17.37
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
12.02
ROE
6.9%
P/B Ratio
0.98
P/FCF
3.61
Gross Margin
37.0%
ROIC
8.8%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
8.8%
WACC
3.6%
ROIC − WACC
+5.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental विश्लेषण मानदंड
पास (16)
- ROIC 8.8%
- Gross Margin 37.0%
- P/FCF 3.61
- P/B Ratio 0.98
- Operating Margin 16.2%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Undervalued)
- ROE 8.4%
- Revenue Growth 5Y 7.1%
- Analyst Consensus 67% Buy
- Earnings Surprise avg 45.6%
- Earnings Quality (OCF/NI) 2.71
- Net Margin Trend 5.3% vs 2.2%
फेल (4)
- Price CAGR -6.74%
- Debt/Equity ratio
- CapEx intensity
- Piotroski F-Score 2/9
अनुपलब्ध (7)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director | 57 |
| Mr. Rahul Srinivasan | Chief Financial Officer | 48 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | 41 |
| Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | - |
| Mr. David Ian Bell | Chief Corporate Affairs & Legal Officer | 71 |
| Mr. Enrique de la Torre | Chief Compliance Officer | 52 |
| Ms. Montse Ribas | Chief Communications and Reputation Officer | 56 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | 44 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | 64 |
| Mr. Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager | 57 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for GRFS, sourced from Markets Gazette.